Grupo de Investigación Miguel Servet Oftalmología (GIMSO), Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, España; Servicio de Oftalmología, Hospital Provincial Nuestra Señora de Gracia, Zaragoza, España.
Grupo de Investigación Miguel Servet Oftalmología (GIMSO), Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, España; Servicio de Oftalmología, Hospital Provincial Nuestra Señora de Gracia, Zaragoza, España.
Arch Soc Esp Oftalmol (Engl Ed). 2020 Nov;95(11):538-543. doi: 10.1016/j.oftal.2020.05.016. Epub 2020 Jun 27.
To evaluate the effects and safety of topical drops of perfluorohexyloctane (F6H8) on the ocular surface and the corneal endothelium.
Forty-five patients (90 eyes) diagnosed with dry eye disease were recruited and prescribed treatment with F6H8 as part of a six-month prospective multicentre study. Variables in corneal staining were documented using the National Eye Institute/Industry Workshop scale. The conjunctival variables included using the Oxford scale, as well as corneal parameters, such as central corneal thickness, cell density, coefficient of variation, hexagonality, and mean cell area, at the start of the study, and at 3months and 6months. Compliance and satisfaction with the treatment were measured.
F6H8 drops reduced mean corneal staining based on the NEI scale in compliant patients to a mean of -0.84 ± 1.95 at 3months (P=.001) and to -1.65 ± 2.42 at 6months (P<.001). Conjunctival staining at 6months showed a mean decrease of -0.13 (P=.319). The endothelial parameters did not show a significant difference, in contrast to the central corneal thickness that showed a statistically significant decrease (545.30 ± 32.25 at the start of the study to 538.40 ± 31.36 after 6months, P=.009). At the end of the study, 46% of patients reported feeling subjectively better, 40.5% felt the same, and 13.5% felt subjectively worse.
Topical treatment with F6H8 for dried eye disease did not alter the measured variables of the corneal endothelium, but showed improvement in corneal staining and satisfaction.
评估全氟己基辛烷（F6H8）滴眼剂对眼表和角膜内皮的作用和安全性。
共招募 45 名（90 只眼）诊断为干眼症的患者，并开具 F6H8 治疗处方，这是一项为期六个月的前瞻性多中心研究的一部分。使用国家眼科研究所/工业研讨会量表记录角膜染色的变量。使用牛津量表记录结膜变量，以及角膜参数，如中央角膜厚度、细胞密度、变异系数、六边形性和平均细胞面积，在研究开始时、3 个月和 6 个月时进行测量。评估治疗的依从性和满意度。
F6H8 滴眼液降低了符合条件的患者基于 NEI 量表的平均角膜染色，3 个月时平均为-0.84±1.95（P=.001），6 个月时平均为-1.65±2.42（P<.001）。6 个月时结膜染色平均下降-0.13（P=.319）。内皮参数没有显示出显著差异，而中央角膜厚度显示出统计学上的显著下降（研究开始时为 545.30±32.25，6 个月后为 538.40±31.36，P=.009）。研究结束时，46%的患者报告主观感觉更好，40.5%的患者感觉相同，13.5%的患者感觉主观上更差。
F6H8 滴眼治疗干燥性眼病不会改变角膜内皮的测量变量，但可改善角膜染色和患者满意度。
